ASCO 2026 Ushers In a New Era for Pancreatic Cancer, Expands Targeted Therapy Options Across the GI Spectrum - OncLive

ASCO 2026 Ushers In a New Era for Pancreatic Cancer, Expands Targeted Therapy Options Across the GI Spectrum  OncLivePancreatic cancer experts, patients applaud new KRAS inhibitor therapy  Fred Hutchinson Cancer CenterDaraxonrasib Extends Median Survival in Previously Treated Pancreatic Cancer  The ASCO PostWinning the lottery with a clinical trial to treat pancreatic cancer  UCLA HealthBreakthrough in Pancreatic Cancer Treatment: New Drug Reduces Death Risk by 60%  Inbox.eu